Atreca Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Out of Business

  • Employees
  • 90

Employees

  • Latest Deal Type
  • Out of Business

Atreca General Information

Description

Developer of novel therapeutics designed to engage the human immune response in oncology and other indications. The company operates a biopharmaceutical platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types.

Contact Information

Website
www.ir.atreca.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 835 Industrial Road
  • Suite 400
  • San Carlos, CA 94070
  • United States
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 835 Industrial Road
  • Suite 400
  • San Carlos, CA 94070
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Atreca Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Out of Business 11-Feb-2025 Completed Out of Business
10. IPO 20-Jun-2019 Completed Generating Revenue
9. Later Stage VC (Series C1) 11-Sep-2018 Completed Generating Revenue
8. Later Stage VC (Series B) 17-Aug-2017 Completed Generating Revenue
7. Early Stage VC (Series A) 20-Oct-2015 Completed Generating Revenue
6. Early Stage VC 30-Aug-2013 Completed Generating Revenue
5. Early Stage VC 25-Sep-2012 Completed Generating Revenue
4. Early Stage VC 19-Apr-2012 Completed Generating Revenue
3. Early Stage VC 02-Mar-2012 $50K $400K Completed Generating Revenue
2. Early Stage VC 29-Feb-2012 $350K $350K Completed Generating Revenue
To view Atreca’s complete valuation and funding history, request access »

Atreca Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series C1
Series C2
Series B 18,008,749 $0.000100 $1.94 $1.94 1x $1.94 12.91%
Series A 32,133,287 $0.000100 $1.85 $1.85 1x $1.85 23.04%
To view Atreca’s complete cap table history, request access »

Atreca Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel therapeutics designed to engage the human immune response in oncology and other indications. The comp
Biotechnology
San Carlos, CA
90 As of 2023

South San Francisco, CA
 

Abingdon, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Atreca Competitors (107)

One of Atreca’s 107 competitors is CytomX Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
Vir Biotechnology Formerly VC-backed San Francisco, CA
Pure MHC Formerly VC-backed Austin, TX
CRISPR Therapeutics Formerly VC-backed Zug, Switzerland
You’re viewing 5 of 107 competitors. Get the full list »

Atreca Patents

  • 92

    Total Documents Applications and Grants

  • Total Patents Families

  • 25

    Granted

  • 12

    Pending

  • Expiring in next 12 mo

Atreca Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025194069-A1 Anti-csp antibody variants Pending 15-Mar-2024
AU-2024214379-A1 Anti-csp antibody variants Pending 03-Feb-2023
EP-4658682-A2 Anti-csp antibody variants Pending 03-Feb-2023
US-20260226147-A1 Anti-csp antibody variants Pending 03-Feb-2023
WO-2024163875-A2 Anti-csp antibody variants Inactive 03-Feb-2023 A61P33/06
To view Atreca’s complete patent history, request access »

Atreca Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

Atreca ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Atreca’s complete esg history, request access »

Atreca FAQs

  • When was Atreca founded?

    Atreca was founded in 2010.

  • Where is Atreca headquartered?

    Atreca is headquartered in San Carlos, CA.

  • What is the size of Atreca?

    Atreca has 90 total employees.

  • What industry is Atreca in?

    Atreca’s primary industry is Biotechnology.

  • Is Atreca a private or public company?

    Atreca is a Private company.

  • What is Atreca’s current revenue?

    The current revenue for Atreca is .

  • How much funding has Atreca raised over time?

    Atreca has raised $348M.

  • Who are Atreca’s competitors?

    CytomX Therapeutics, Adaptimmune Therapeutics, Vir Biotechnology, Pure MHC, and CRISPR Therapeutics are some of the 107 competitors of Atreca.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process